These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9520456)

  • 1. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.
    Zagury D; Lachgar A; Chams V; Fall LS; Bernard J; Zagury JF; Bizzini B; Gringeri A; Santagostino E; Rappaport J; Feldman M; Burny A; Gallo RC
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3851-6. PubMed ID: 9520456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repair of the in vitro HIV-1-induced immunosuppression and blockade of the generation of functional suppressive CD8 cells by anti-alpha interferon and anti-Tat antibodies.
    Lachgar A; Bernard J; Bizzini B; Astgen A; Le Coq H; Fouchard M; Chams V; Feldman M; Burny A; Zagury JF
    Biomed Pharmacother; 1996; 50(1):13-8. PubMed ID: 8672726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
    Gallo RC; Burny A; Zagury D
    DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
    Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
    Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.
    Viscidi RP; Mayur K; Lederman HM; Frankel AD
    Science; 1989 Dec; 246(4937):1606-8. PubMed ID: 2556795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat.
    Poznansky MC; Foxall R; Mhashilkar A; Coker R; Jones S; Ramstedt U; Marasco W
    Hum Gene Ther; 1998 Mar; 9(4):487-96. PubMed ID: 9525310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies.
    Mhashilkar AM; LaVecchio J; Eberhardt B; Porter-Brooks J; Boisot S; Dove JH; Pumphrey C; Li X; Weissmahr RN; Ring DB; Ramstedt U; Marasco WA
    Hum Gene Ther; 1999 Jun; 10(9):1453-67. PubMed ID: 10395371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV type 1 Tat protein enhances activation-but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals.
    Katsikis PD; García-Ojeda ME; Torres-Roca JF; Greenwald DR; Herzenberg LA; Herzenberg LA
    Int Immunol; 1997 Jun; 9(6):835-41. PubMed ID: 9199966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
    Gallo RC
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
    [No Abstract]   [Full Text] [Related]  

  • 13. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.
    Barillari G; Gendelman R; Gallo RC; Ensoli B
    Proc Natl Acad Sci U S A; 1993 Sep; 90(17):7941-5. PubMed ID: 7690138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Tat modulates T-bet expression and induces Th1 type of immune response.
    Kulkarni A; Ravi DS; Singh K; Rampalli S; Parekh V; Mitra D; Chattopadhyay S
    Biochem Biophys Res Commun; 2005 Apr; 329(2):706-12. PubMed ID: 15737643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients.
    Re MC; Furlini G; Vignoli M; Ramazzotti E; Zauli G; La Placa M
    Clin Diagn Lab Immunol; 1996 Mar; 3(2):230-2. PubMed ID: 8991642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis.
    Ehret A; Westendorp MO; Herr I; Debatin KM; Heeney JL; Frank R; Krammer PH
    J Virol; 1996 Sep; 70(9):6502-7. PubMed ID: 8709290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.
    Gutheil WG; Subramanyam M; Flentke GR; Sanford DG; Munoz E; Huber BT; Bachovchin WW
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6594-8. PubMed ID: 7912830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
    Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
    Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
    Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
    DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.